Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03695406 · ClinicalTrials.gov registry record · NA

Mind Body Program for Fear of Recurrence

A NA study of Cancer Survivors, sponsored by Beth Israel Deaconess Medical Center.

Completed
Registry status
NA
Development phase
23
Enrollment target
1
Study location

NCT03695406: Completed NA study of Cancer Survivors, sponsored by Beth Israel Deaconess Medical Center.

NCT03695406 is a NA study of Cancer Survivors that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 23 participants, below the 116-participant average among 11 other Cancer Survivors trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03695406, a NA study of Cancer Survivors, has completed, sponsored by Beth Israel Deaconess Medical Center.

COMPLETED
Registry status
NA
Development phase
23 participants
Enrollment target
1
Study location

Study Summary

This is a pilot feasibility study of a group-based, mind body intervention for managing stress and fear of recurrence and promoting resiliency among adult cancer survivors.

Primary Outcome

The primary metric for assessing Feasibility will be retention at the initial follow-up assessment. Reasons for ineligibility, refusal, or dropping out will be measured.

Conditions Studied

Cancer Survivors

Interventions

  • BEHAVIORAL Mind-Body Program for Fear of Recurrence

Study Locations (1)

Massachusetts

  • Beth Israel Deaconess Medial Center - Boston

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2017-08-09
Est. Completion 2022-01-07
Phase NA
Beth Israel Deaconess Medical Center

488 total trials

What the finished NCT03695406 record still lists

NCT03695406 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 116-participant average among 11 other Cancer Survivors trials with a reported enrollment target (80% lower).

The record links to 1 condition, with Cancer Survivors appearing as the primary indexed condition, and to 1 intervention - of which Mind-Body Program for Fear of Recurrence is the first listed.

NCT03695406 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03695406 about?

NCT03695406 is a clinical study titled "Mind Body Program for Fear of Recurrence". This is a pilot feasibility study of a group-based, mind body intervention for managing stress and fear of recurrence and promoting resiliency among adult cancer survivors.

What is the current status of trial NCT03695406?

This trial is currently completed. It is a NA study. The enrollment target is 23 participants. The study started on 2017-08-09. Estimated completion is 2022-01-07.

What conditions does trial NCT03695406 study?

This clinical trial studies the following conditions: Cancer Survivors.

What interventions are being tested in trial NCT03695406?

The interventions under investigation include: Mind-Body Program for Fear of Recurrence (BEHAVIORAL).

Who is sponsoring clinical trial NCT03695406?

This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03695406 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cancer Survivors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03695406's enrollment target sits among peer trials

23 9th of 11 higher than 3 of 11 other Cancer Survivors trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cancer Survivors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03616041 · 23 participants

    Capsule Endoscopy for Severe Hematochezia

  • NCT04348747 · 23 participants · Phase 2

    Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

  • NCT04587687 · 23 participants · Phase 2

    Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

  • NCT04715022 · 23 participants · Phase 1

    Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03695406, the US trial registry maintained by the National Library of Medicine. NCT03695406 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.